These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 17507039)

  • 1. Re: expression of major heat shock proteins in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. T. Kurahashi, H. Miyake, I. Hara and M. Fujisawa J Urol 2007; 177: 757-761.
    Vale S
    J Urol; 2007 Jul; 178(1):352-3. PubMed ID: 17507039
    [No Abstract]   [Full Text] [Related]  

  • 2. Expression of major heat shock proteins in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.
    Kurahashi T; Miyake H; Hara I; Fujisawa M
    J Urol; 2007 Feb; 177(2):757-61. PubMed ID: 17222676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HSP27 and HSP70 interact with CD10 in C4-2 prostate cancer cells.
    Dall'Era MA; Oudes A; Martin DB; Liu AY
    Prostate; 2007 May; 67(7):714-21. PubMed ID: 17342744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of prostate cancer with finasteride.
    Ross RK; Skinner E; Cote RJ
    N Engl J Med; 2003 Oct; 349(16):1569-72; author reply 1569-72. PubMed ID: 14562807
    [No Abstract]   [Full Text] [Related]  

  • 5. Prevention of prostate cancer with finasteride.
    Barzell WE
    N Engl J Med; 2003 Oct; 349(16):1569-72; author reply 1569-72. PubMed ID: 14562803
    [No Abstract]   [Full Text] [Related]  

  • 6. Prevention of prostate cancer with finasteride.
    Burke HB
    N Engl J Med; 2003 Oct; 349(16):1569-72; author reply 1569-72. PubMed ID: 14562806
    [No Abstract]   [Full Text] [Related]  

  • 7. Prevention of prostate cancer with finasteride.
    Rubin MA; Kantoff PW
    N Engl J Med; 2003 Oct; 349(16):1569-72; author reply 1569-72. PubMed ID: 14561801
    [No Abstract]   [Full Text] [Related]  

  • 8. The utility of 5-alpha reductase inhibitors in the prevention and diagnosis of prostate cancer.
    Reed AB; Parekh DJ
    Curr Opin Urol; 2009 May; 19(3):238-42. PubMed ID: 19318950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preventing prostate cancer with finasteride: a mixed blessing.
    Harv Mens Health Watch; 2003 Oct; 8(3):1-3. PubMed ID: 14576014
    [No Abstract]   [Full Text] [Related]  

  • 10. Prevention of prostate cancer with finasteride.
    Lee SC; Ellis RJ
    N Engl J Med; 2003 Oct; 349(16):1569-72; author reply 1569-72. PubMed ID: 14562805
    [No Abstract]   [Full Text] [Related]  

  • 11. Case records of the Massachusetts General Hospital. Case 15-2008. A 55-year-old man with an elevated prostate-specific antigen level and early-stage prostate cancer.
    Barry MJ; Kaufman DS; Wu CL
    N Engl J Med; 2008 May; 358(20):2161-8. PubMed ID: 18480209
    [No Abstract]   [Full Text] [Related]  

  • 12. A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefits.
    Montorsi F; Alcaraz A; Desgrandchamps F; Hammerer P; Schröder F; Castro R
    Prostate; 2009 Jun; 69(8):895-907. PubMed ID: 19267353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re: Long-term effects of finasteride on prostate specific antigen levels: results from the Prostate Cancer Prevention Trial.
    Walsh PC
    J Urol; 2006 Jul; 176(1):409-10; author reply 410. PubMed ID: 16753454
    [No Abstract]   [Full Text] [Related]  

  • 14. Down-regulation of Hsp27 radiosensitizes human prostate cancer cells.
    Teimourian S; Jalal R; Sohrabpour M; Goliaei B
    Int J Urol; 2006 Sep; 13(9):1221-5. PubMed ID: 16984557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Finasteride for prevention of prostate cancer.
    Med Lett Drugs Ther; 2008 Jun; 50(1289):49-50. PubMed ID: 18583946
    [No Abstract]   [Full Text] [Related]  

  • 16. Heat shock proteins 27, 60 and 70 as prognostic markers of prostate cancer.
    Glaessgen A; Jonmarker S; Lindberg A; Nilsson B; Lewensohn R; Ekman P; Valdman A; Egevad L
    APMIS; 2008 Oct; 116(10):888-95. PubMed ID: 19132982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The value of immunohistochemical research on PCNA, p53 and heat shock proteins in prostate cancer management: a review.
    Cappello F; Ribbene A; Campanella C; Czarnecka AM; Anzalone R; Bucchieri F; Palma A; Zummo G
    Eur J Histochem; 2006; 50(1):25-34. PubMed ID: 16584982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 5alpha-reductase inhibitors in benign prostatic hyperplasia and prostate cancer risk reduction.
    Rittmaster RS
    Best Pract Res Clin Endocrinol Metab; 2008 Apr; 22(2):389-402. PubMed ID: 18471794
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppressive effects of antiandrogens, finasteride and flutamide on development of prostatic lesions in a transgenic rat model.
    Cho YM; Takahashi S; Asamoto M; Suzuki S; Tang M; Shirai T
    Prostate Cancer Prostatic Dis; 2007; 10(4):378-83. PubMed ID: 17457304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer.
    Thomas LN; Douglas RC; Lazier CB; Too CK; Rittmaster RS; Tindall DJ
    Eur Urol; 2008 Feb; 53(2):244-52. PubMed ID: 18006217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.